The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker

European Journal of Cancer

Volumn 37, Issue SUPPL. 1, 2001, Pages 3-10

  Cooke, T ^a   Reeves, J ^a   Lannigan, A ^a   Stanton, P ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; HER2; Nottingham Prognostic Index; Prognosis

Indexed keywords

GAMMA UROGASTRONE; GENE PRODUCT; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; BREAST CELL; CANCER GRADING; CANCER RISK; CANCER SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

EID: 0035122438     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00402-0     Document Type: Article

References (77)

1. Progesterone receptors as a prognostic factor in stage II breast cancer
2. The biology of erbB-2/neu/HER-2 and its role in cancer
3. The Nottingham Prognostic Index in primary breast cancer
4. Prognosis and prediction of response in breast cancer: The current role of the main biological markers
5. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
6. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor
7. Amplification of the int-2 gene in primary human breast tumours
8. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas
9. p53 in the diagnosis of human neoplasia
10. Direct sequencing from touch preparations of human carcinomas: Analysis of p53 mutations in breast carcinoma
11. Comparative study of Harvey-ras oncogene expression with conventional clinicopathologic parameters of breast cancer
12. Pathobiologic identifiaction of two distinct breast carcinoma subsets with diverging clinical behaviors
13. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation
14. EGF-related peptides and their receptors in mammary gland development
15. EGF-related peptides in the pathophysiology of the mammary gland
16. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer
17. Dynamic expression and activation of ErbB receptors in the developing mouse mammary gland
18. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
19. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling
20. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
21. Overexpression of the c-erbB-2 oncogene: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance
22. Quantitation of EGFR and c-erbB-2 expression in preinvasive compared to invasive breast cancer
23. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
24. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
25. HER2 causes transformation and tumorigenesis of NIH 3T3 cells
26. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
27. Treatment of breast cancer
28. Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development
29. HER2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
30. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
31. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women
32. Polychemotherapy for early breast cancer: An overview of the randomized trials
33. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
34. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
35. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
36. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
37. HER-2/neu amplification predicts poor survival in node-positive breast cancer
38. Prognostic importance of c-erbB-2 expression in breast cancer
39. Prognostic value of CerbB2 overexpression in axillary lymph node-positive breast cancer. Results from a randomized adjuvant treatment protocol
40. Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastases and poor long-term survival in breast cancer
41. C-erb B2 oncoprotein expression in primary and advanced breast cancer
42. Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer
43. Expression of HER-2/neu oncoprotein in breast cancer: A comparison of immunohistochemical and western blot techniques
44. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
45. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors
46. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
47. Prognostic significance of Her-2/neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
48. The long term prognostic significance of C-erb B2 in primary breast cancer
49. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11
50. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
51. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer
52. The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer
53. HER2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
54. Prognostic significance of c-erbB-2 expression in node negative breast cancer
55. Follow-up study of HER-2/neu amplification in primary breast cancer
56. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast
57. Overexpression of HER-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer
58. Ductal carcinoma in situ of the breast: Correlation between histologic classifications and biologic markers
59. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: Correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity
60. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
61. HER2 overexpression in various tumor types
62. The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer
63. HER2 expression and response to tamoxifen in oestrogen receptor positive breast cancer: A Southwest Oncology Study Group study
64. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study
65. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi
66. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer
67. Quantitation of c-erbB-2 in primary breast cancer allows identification of a further poor prognostic group
68. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
69. An ovarian hormone: Preliminary reports on its localization, extraction and partial purification and action in test animals
70. Fate of steroidal estrogens in target tissues
71. Oestrogen receptors and survival in early breast cancer
72. Estrogen and progesterone receptor determinations in breast cancer: Technology, biology and clinical significance
73. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer
74. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer
75. HER2 antibody for human cancer therapy
76. Multinational Herceptin Investigator Group Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)